GENZYME CORPORATION for GENZYME CORPORATION
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Trade Promotion Authority legislation and other trade issues, including the Trans-Pacific Partnership (TPP) Protection and promotion of 12 years exclusivity for biosimilars Protection and Promotion of Orphan Drug Act market exclusivity
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA BARTLETT | — |
| SARA FROELICH | — |
Taxation/Internal Revenue Code TAX
Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Excise tax for drugs and biologics Issues and policies related to Orphan Drug Tax Credit Implementation of American Taxpayer Relief Act of 2012 Issues and policies related to tax reform H.R. 880, American Research and Competitiveness Act of 2015 S. 537, Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation Act of 2015(COMPETE Act) Corporate tax inversions issues Legislation pertaining to the applicability of the ACA tax carve out for non-orphan drug designated drugs, generally, including H.R. 3678, Preserving Access to Orphan Drugs Act of 2015 H.R. 3618 and S. 1906, Orphan Drug Fairness Act Protecting Americans From Tax Hikes Act of 2015 (PATH)
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA BARTLETT | — |
| SARA FROELICH | — |
Copyright/Patent/Trademark CPT
Patent settlement legislation, including HR 9, Innovation Act of 2015, S. 632, STRONG Patents Act of 2015, and S.1137, PATENT Act S.2019, Preserve Access to Affordable Generics Act
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA BARTLETT | — |
| SARA FROELICH | — |
Health Issues HCR
Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) 340B issues and legislative reform proposals Issues related to importation of prescription drugs, including those contained in S. 122, Safe and Affordable Drugs from Canada Act of 2015 Health technology assessment of orphan drugs Sequestration of FDA user fees H.R. 1376, Patient Choice Act of 2015 H.R. 790, Compassionate Freedom of Choice Act of 2015 H.R. 1600, Patients' Access to Treatments Act of 2015 21st Century Cures/Innovation initiatives including H.R. 6, 21st Century Cures Act and the Innovation for Healthier Americans Initiative, including the following: S. 2055, The Medical Countermeasures Innovation Act of 2015; S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act; S. 2030, The Advancing Targeted Therapies for Rare Diseases Act of 2015; S. 849, Advancing Research for Neurological Diseases Act of 2015; S. 2700, FDA and NIH Workfroces Authorities Modernization Act H.R. 909, Andrea Sloan CURE Act S. 1421 and H.R.971, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015 Implementation of the FDA Safety and Innovation Act (FDASIA) (Pub. L. 112-144) Regulation of innovative biological products for neurodegenerative diseases Issues and policies related to implementation of Orphan Drug Act and orphan drug development S. 320, Medical Innovation Act H.R. 744, Medical Innovation Act S. 2615, Increasing Competition in Pharmaceuticals Act H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015 H.R. 1531 and S.1878, Advancing Hope Act of 2015 Implementation of newborn screening programs Issues and policies related to biosimilars exclusivity period Issues and policies related to biosimilars FDA guidance Issues and policies related to FDA oversight and management Issues and policies related to expanded access programs Issues and policies related to patient involvement with FDA decision making S. 289 and H.R. 2104, American Cures Act Legislation pertaining to FDA priority review vouchers, generally Legislation pertaining to the applicability of the ACA tax carve out for non-orphan drug designated drugs, generally, including H.R. 3678, Preserving Access to Orphan Drugs Act of 2015 H.R. 3618 and S. 1906, Orphan Drug Fairness Act Issues related to the value of prescription medicines, generally, and including S. 2023, Prescription Drug Affordability Act of 2015 Drug shortage issues Issues related to health care transparency
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA BARTLETT | — |
| SARA FROELICH | — |
Medicare/Medicaid MMM
Part D drug coverage and patient access issues and policy ESRD bundling and drug reimbursement issues HCPCS coding and reimbursement decisions Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Least costly alternative (LCA) policy Changes re: Medicare Part B and Average Sales Price Medicare secondary payor for ESRD services Extension of rebates on Medicare Part D drugs Performance measures for bone and mineral metabolism for ESRD program Implementation of American Taxpayer Relief Act of 2012 H.R. 1416, Cancer Patient Protection Act of 2015 21st Century Cures/Innovation initiatives, including H.R. 6, 21st Century Cures Act S. 506, To amend Part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes H.R. 696, To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes Medicaid drug rebate, drug coverage and patient access to therapies issues and policy S. 31, Medicare Prescription Drug Price Negotiation Act of 2015 H.R. 1130, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 598, Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 S. 648, Medicare Formulary Improvement Act of 2015 H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015 H.R.2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA BARTLETT | — |
| SARA FROELICH | — |
Budget/Appropriations BUD
Funding for FDA and NIH Issues and policies related to FY 2017 Appropriations and all applicable amendments H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015 H.R.3762, To provide for reconciliation pursuant to section 2002 of the concurrent resolution on the budget for FY 2016 Issues and policies related to H.Con.Res. 125, House FY 2017 budget resolution and all applicable amendments
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA BARTLETT | — |
| SARA FROELICH | — |
Pharmacy PHA
Food and Drug Administration Safety and Innovation Act (FDASIA) implementation Issues and policies related to biosimilars exclusivity period Biosimilars FDA guidance Implementation of Drug Quality and Security Act Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) Issues and policies related to FDA oversight and management Issues and policies related to expanded access programs Issues and policies related to patient involvement with FDA decision making
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA BARTLETT | — |
| SARA FROELICH | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.